BRCA2 reversion mutation confers resistance to olaparib in breast cancer

A rare missense mutation was identified as a reversion mutation using cancer genomic profiling and a suspected mechanism underlying resistance to olaparib in breast cancer.

[1]  Mingchao Xie,et al.  Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets , 2022, BMC Cancer.

[2]  Xiaojia Wang,et al.  BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis , 2021, Journal of breast cancer.

[3]  J. Armenia,et al.  A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Tutt,et al.  Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. , 2020, Cancer discovery.

[5]  Q. Cheng,et al.  PARP inhibitor resistance: the underlying mechanisms and clinical implications , 2020, Molecular Cancer.

[6]  E. Winer,et al.  Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer , 2019, bioRxiv.

[7]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.

[8]  P. Stephens,et al.  BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. , 2017, Clinical breast cancer.

[9]  L. Borsu,et al.  Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer , 2017, Clinical Cancer Research.

[10]  A. Ashworth,et al.  Modeling Therapy Resistance in BRCA1/2-Mutant Cancers , 2017, Molecular Cancer Therapeutics.

[11]  A. Richardson,et al.  CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. , 2016, Cell reports.

[12]  C. Walsh.  Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. , 2015, Gynecologic oncology.